Current Edition

AZ teams up with G1 on lung cancer combination therapy

AstraZeneca has signed a deal with US group G1 Therapeutics to test the potential of a new combination therapy for lung cancer.
The parties have signed a clinical trials collaboration that pairs AZ’ Tagrisso (osimertinib) with G1’s oral CDK4/6 inhibitor G1T38 in EGFR mutation-positive non-small cell lung cancer (NSCLC).
Under the agreement, G1 will sponsor and conduct a Phase Ib/II study in collaboration with AZ, scheduled to start in the first quarter of next year, in patients with NSCLC who have experienced disease progression on first-line EGFR inhibitors and carry the EGFR T790M mutation.
After determining the recommended dose of the combination in the Phase Ib part of the trial, the Phase II trial will then assess progression free survival in patients given either Tagrisso monotherapy or Tagrisso plus G1T38.
“CDK4/6 inhibitors can enhance the efficacy of targeted therapies, and G1T38 has already shown encouraging preclinical and initial clinical data that support a potential best-in-class profile,” noted Mark Velleca, G1’s chief executive.
“The addition of G1T38 to Tagrisso in EGFR mutation-positive NSCLC has the potential to prolong the time to disease progression by overcoming resistance mechanisms,” he added.
Financial specifics of the deal were not revealed.